Semaglutide

Semaglutide (marketed under brand names such as Ozempic and Wegovy) is a GLP-1 receptor agonist prescribed for weight management, blood sugar control in type 2 diabetes, and the reduction of major cardiovascular risks including heart attack and stroke in certain patients.

Administered once weekly by subcutaneous injection, Semaglutide works by mimicking the action of the natural hormone GLP-1. It stimulates insulin release in response to meals, reduces the secretion of glucagon, slows the rate of gastric emptying, and helps curb appetite. Together, these mechanisms contribute to improved glucose regulation, sustained weight loss, and better overall metabolic health.